Background {#Sec1}
==========

To date, pancreaticoduodenectomy (PD) has been regarded as the only potentially curative treatment for pancreatic head and periampullary tumors, including tumors in the ampullary region, distal biliary duct, and periampullary duodenum \[[@CR1]\]. A retrospective study in which 1000 cases were recruited over the past three decades showed that PD has become an effective treatment to reduce hospital mortality \[[@CR2]\]. Mortality has been reduced to less than 5 %, but the morbidity remains at 30--50 % \[[@CR2], [@CR3]\]. Postoperative pancreatic fistula (POPF) is one of the most frequent and ominous complications after PD, and its occurrence reportedly ranges from 2--40 % \[[@CR4], [@CR5]\]. Severe POPF prolongs hospital stay and requires the use of specific treatments, such as the use of antibiotics, nutritional support, endoscopy, interventional radiology, and/or reoperation, etc. \[[@CR6]\]. POPF risk is increased by many factors including pancreatic texture, main pancreatic duct diameter, and pancreaticojejunal (PJ) anastomotic technique \[[@CR7]--[@CR9]\]. Among these factors, only anastomotic technique can be improved. According to the International Study Group of Pancreatic Surgery (ISGPS) definition, POPF exists if the drainage of any measurable volume of fluid containing amylase exceeds three times the normal serum value on or after postoperative day (POD) 3 \[[@CR10]\].

Several anastomotic surgical techniques have been developed to reduce the incidence of pancreatic fistula in recent decades, including the duct-to-mucosa method, pancreaticogastrostomy, Peng's binding method, and the "end-to-end" or "end-to-side" invaginated method. Among these techniques, the conventional duct-to-mucosa method remains the most popular anastomosis due to its advantages. The size of the pancreatic remnant is not limited; moreover, the jejunal lumen and pancreatic remnant lead to easier anastomosis \[[@CR11]--[@CR14]\].

Compared with two-layer duct-to-mucosa anastomosis, the novel one-layer duct-to-mucosa PJ anastomosis method has been reported to be efficient at reducing POPF occurrence \[[@CR15], [@CR16]\]. However, the two cited retrospective studies might lead to selection bias. Because this evidence is insufficient, we will conduct a randomized controlled trial to verify the superiority of one-layer duct-to-mucosa PJ anastomosis after PD over the two-layer technique.

Methods/design {#Sec2}
==============

Study aim {#Sec3}
---------

The aim of this study is to compare the effect of two duct-to-mucosa PJ anastomotic methods for PD by assessing factors that are related to mortality or morbidity, including postoperative pancreatic fistula rate, biliary leakage, postpancreatectomy hemorrhage, and anastomosis time.

Patient involvement {#Sec4}
-------------------

Sample size calculation is based on the primary endpoint: POPF rate. According to published data, an assumed absolute risk of 22 % difference in POPF occurrence is the appropriate basis for the calculation assuming 4.5 % POPF in the one-layer technique group and 26.7 % in the two-layer technique group \[[@CR15], [@CR16]\]. This calculation yields a total of 51 patients in each group, which assures a power of 90 % at a two-sided level of significance of 5 % (NCSS and PASS 11 (NCSS Statistical Software, Kaysville, UT, USA)). Assuming an expected withdrawal rate of 10 % during the trial, 12 additional patients will be included and randomized; therefore, the total sample size required is *n* = 114 patients (Fig. [1](#Fig1){ref-type="fig"}) (Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}).Fig. 1Flow chart according to CONSORT

Eligibility criteria {#Sec5}
--------------------

### Inclusion criteria {#Sec6}

Patients who meet the following criteria will be included in the study:Age 18--80 yearsElective pancreaticoduodenectomyProvision of informed consent.

### Exclusion criteria {#Sec7}

Patients who meet any of the following criteria will be excluded from the study:Patients with any severe cardiopulmonary disease: American Society of Anesthesiologists (ASA) classification or ejection fraction below 30 % that might prolong the postoperative hospital stayPrevious pancreatic operationImmunodeficiency, such as that observed under HIVEmergency operationPregnancy.

### Withdrawal {#Sec8}

Patients can withdraw from the trial at their own request or at the request of their legal representative at any time. Patients may be removed if, in the investigator's opinion, continuation of the trail could be detrimental to the patient's well-being or if a PD is not performed due to technical unresectability, metastatic disease, or other reasons. Every withdrawal will be recorded in the clinical report forms (CRFs) and in the patient's medical case records. All examinations scheduled for the final trial day will be performed on all patients and documented. All data will be analyzed according to the intention-to-treat (ITT) principle \[[@CR17]\].

### Ethics, study registration, and consent {#Sec9}

The final protocol has been approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (approval number: KY201502). The trial protocol has also been registered in the protocol registration system at ClinicalTrials.gov (identifier: NCT02511951). All patients will be scheduled only after comprehensive information concerning the nature, scope, and possible consequences of the clinical trial has been provided to them in an understandable way by the investigator. Written informed consent for the study will be obtained from each patient before the operation. The study procedure, benefits, risks, and data management will be clarified in detail during the preoperative conversation.

Trial interventions {#Sec10}
===================

One-layer duct-to-mucosa PJ anastomosis {#Sec11}
---------------------------------------

For the one-layer technique group, to create the posterior suturing layers, double needles with a 4--0 Prolene line (Ethicon, Shanghai, China) will be used; one side of the needles will be inserted from the posterior inner side of the pancreatic duct and out through the dorsal parenchyma of the pancreatic stump to the posterior surface of the pancreas at a point approximately 0.5 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel (Fig. [2](#Fig2){ref-type="fig"}). The anterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be inserted into the duct of the pancreatic remnant according to its size. Drain tubes will be placed anterior and posterior to the anastomosis (one each) when the anastomosis has been completed (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2The procedure of end-to-side one-layer duct-to-mucosa PJ anastomosis: the posterior suturing layerFig. 3The anterior suturing layer with duct-to-mucosa PJ anastomosis

Two-layer duct-to-mucosa PJ anastomosis {#Sec12}
---------------------------------------

For the two-layer continuous suture method, the same double needle and 4--0 Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the continuous suturing method (Fig. [4](#Fig4){ref-type="fig"}). The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the continuous suturing method with Prolene line, and a suitable internal pancreatic duct stent will then be placed approximately 4--6 cm into the main duct (Fig. [5](#Fig5){ref-type="fig"}). The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the continuous method. Drain tubes will be managed as described above.Fig. 4The procedure of end-to-side two-layer duct-to-mucosa PJ anastomosis: the seromuscular layerFig. 5The procedure of two-layer duct-to-mucosa PJ anastomosis: duct-to-mucosa layer

Primary and secondary endpoints {#Sec13}
-------------------------------

### Primary endpoint {#Sec14}

The primary efficacy endpoint of the trial will be the POPF occurrence rate. POPF is defined by the International Study Group of Pancreatic Fistula (ISGPF) as any measurable volume of drain fluid that contains three times higher amylase content than the normal upper serum value, on or after POD 3. Amylase will be assessed on PODs 1, 3, 5, and 7. Three grades of POPF are determined according to clinical severity: A, B, and C \[[@CR10]\].

### Secondary endpoints {#Sec15}

Secondary outcomes will be postoperative hospital stay, anastomosis time, postpancreatectomy hemorrhage, biliary leak, delayed gastric emptying, wound infection, intra-abdominal fluid collection or abscess, relaparotomy, and mortality. Existent ISGPS definitions will be used to ensure the comparability and generalizability of the results (Table [1](#Tab1){ref-type="table"}). Postoperative complications will be graded based on severity according to the Clavien-Dindo definition \[[@CR18]\] (Table [2](#Tab2){ref-type="table"}).Table 1Definition of secondary endpointsSecondary endpointDefinition and assessment of outcomesAnastomosis timeTime from beginning to end of PJ anastomosisMortalityDeath due to any cause until 90 days after the operation and the reasonMorbidityPostoperative complications will be recorded until 90 days after operation. The severity of complications will be graded according to the Clavien-Dindo classification \[[@CR18]\]Postoperative hospital stayTime from day of operation until discharge (days)Postpancreatectomy hemorrhageEvidence of blood loss from drains and/or nasogastric tube, based on ultrasonography, as defined by ISGPS \[[@CR19]\]Biliary leakBilirubin concentration in the drain fluid at least three times the serum bilirubin concentration as defined by International Study Group of Liver Surgery \[[@CR20]\]Delayed gastric emptyingFailure to resume solid diet with prolonged need for nasogastric tube as defined by ISGPS \[[@CR21]\]Intra-abdominal fluid collectionCollection of fluid measuring ≥3 cm associated with clinical or laboratory abnormalitiesWound infectionSurgical site infection associated with laparotomy that develops during the initial hospital stayPneumoniaPresence of a new infiltrate on chest X-ray, as well as following: body temperature \>38 °C, abnormal elevation of white blood cells, or positive sputum, and requiring antibiotic treatmentAbdominal ruptureDehiscence of abnormal closure with need for resuture of the laparotomy during the initial hospital stayTable 2Complication grades according to the Clavien-Dindo classication scheme^a^GradeDefinitionIAny deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventionIIRequiring pharmacological treatment with drugs other than those allowed for grade I complicationsIIIRequiring surgical, endoscopic, or radiological interventionIIIaIntervention not under general anesthesiaIIIbIntervention under general anesthesiaIVLife-threatening complication. Requiring intensive care unit managementIVaSingle organ dysfunctionIVbMulti-organ dysfunctionVDeath of patient^a^The Clavien-Dindo classification system is reported in detail elsewhere \[[@CR18]\]

Type of trial {#Sec16}
-------------

This is a prospective, randomized, interventional, and patient-blinded, single-center trial comparing two parallel groups.

### Randomization {#Sec17}

To achieve intervention groups with comparable known and unknown risk factors, randomization will be performed. The randomization number will be generated using computer-generated random numbers with an allocation ratio of 1:1 (an equal probability of assignment to either group). All patients will be randomized using consecutively numbered opaque envelopes that will have been sealed by the investigators. The envelopes will be opened before PJ reconstruction and after resection of the lesion from the pancreatic or periampullary region.

### Blinding {#Sec18}

Patients and outcome observers will be blinded with respect to the trial intervention. Blinding of the surgeons and people involved in the operation is not feasible due to the nature of the interventions.

Data management and quality assurance {#Sec19}
-------------------------------------

An independent study doctor (SBP), who will not be involved in the treatment and monitoring of the patients within the operating room, will enter all required data in the prepared CRF. This CRF will be completed as soon as possible, preferably on the day of the patient's treatment and visit (Table [3](#Tab3){ref-type="table"}). Reasonable explanations should be given for all missing data. Complete CRF pages will be checked by the principal investigator and the responsible monitor with respect to completeness and plausibility.Table 3Flow chart of the trialScreeningVisit 1Visit 2Visit 3Visit 3Visit 3Visit 4Before surgeryDay of surgery(POD^b^ 1)(POD 3)(POD 7)(POD 90)Selection criteriaInformed consent×Past medical historyPersonal data^a^×Physical examination×Laboratory tests×××××Trial intervention×Intraoperative outcomes×Postoperative outcomes××××^a^Height (cm), weight (kg), gender, immunosuppressant medication, antibiotics, chemotherapy^b^Postoperative day

Statistical analysis {#Sec20}
--------------------

The two-sided null hypothesis for the primary endpoint measurement states that both study interventions will lead to a similar POPF occurrence rate; the alternative hypothesis is that one intervention will perform better than the other. The null hypothesis will be tested by analyzing the covariance while adjusting for pancreatic texture (soft or hard) and main pancreatic duct diameter (\<3 mm or ≥3 mm). A binary logistic regression will be applied to compare the POPF occurrence rates between the groups after adjusting for other factors. Background characteristics and surgical outcome measures will be compared using chi-squared or Fisher's exact tests for categorical data and two-tailed *t* tests or nonparametric Mann--Whitney *U* tests for continuous variables. Categorical data will be presented as frequencies and group percentages, and continuous variables will be expressed as the means and standard deviations. The homogeneity of two groups will be described by comparison of the demographic data and baseline values. All analyses will be performed on an ITT basis \[[@CR17]\]. For the ITT analysis, the data will be processed for all trial patients in their randomized groups. A *P* value \< 0.05 will be considered statistically significant. All statistical calculations will be performed using SPSS10.0 (SPSS, Chicago, IL, USA).

Discussion {#Sec21}
==========

Currently, pancreaticoduodenectomy is a routine operation, and postoperative mortality is less than 5 % \[[@CR2], [@CR3]\]. POPF is among the most frequently encountered complications that contribute to a high postoperative mortality. Debate regarding the preferred surgical technique for PJ anastomosis has continued for decades. Many retrospective studies have suggested that the POPF occurrence rate is reduced by using a one-layer rather than a two-layer duct-to-mucosa PJ anastomosis \[[@CR15], [@CR16]\]. However, more reliable evidence should be accumulated to address the advantages and disadvantages of both techniques. In this way, the most beneficial technique can be selected for individual patients. Therefore, the factors affecting the success of one-layer versus two-layer duct-to-mucosa PJ anastomosis should be evaluated in this randomized controlled trial to minimize the POPF rates associated with PD.

Trial status {#Sec22}
============

The trail is currently recruiting patients. All patients should be recruited by December 2018.
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=============
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